Development of a [ 177 Lu]BPAMD Labeling Kit and an Automated Synthesis Module for Routine Bone Targeted Endoradiotherapy
Authors:
- 1 March 2015
- journal article
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 30 (2) , 94-99
Abstract
Painful bone lesions, both benign and metastatic, are often managed using conventional analgesics. However, the treatment response is not immediate and is often associated with side-effects. Radionuclide therapy is used for pain palliation in bone metastases as well as some benign neoplasms. Endoradiotherapy has direct impact on the pain-producing bone elements, and hence, response is significant, with minimal or no side-effects. A new potential compound for endoradiotherapy is [(177)Lu]BPAMD. It combines a highly affine bisphosphonate, covalently bridged with DOTA through an amide bond, with the low-energy β(-) emitting therapeutic radiolanthanide (177)Lu. For routine chemical application, an automated synthesis of this radiopharmaceutical and a Kit-type labeling procedure appears to be a basic requirement for its good manufacturing practice (GMP) based production. A Kit formulation combining BPAMD, acetate buffer, and ethanol resulted in almost quantitative labeling yields. The use of ethanol and ascorbic acid as quenchers prevented radiolysis over 48 hours. An automated synthesis unit was designed for the production of therapeutic doses of [(177)Lu]BPAMD up to 5 GBq. The procedure was successfully applied for patient treatments.Keywords
This publication has 13 references indexed in Scilit:
- Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval SummaryClinical Cancer Research, 2014
- In vivo comparison of DOTA based 68Ga-labelled bisphosphonates for bone imaging in non-tumour modelsNuclear Medicine and Biology, 2013
- 68Ga-BPAMD: PET-imaging of bone metastases with a generator based positron emitterNuclear Medicine and Biology, 2012
- Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICSDalton Transactions, 2011
- Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of DiseaseChemical Reviews, 2010
- PET/CT imaging of osteoblastic bone metastases with 68Ga-bisphosphonates: first human studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2010
- EANM procedure guideline for treatment of refractory metastatic bone painEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Lanthanide(III) Complexes of Bis(phosphonate) Monoamide Analogues of DOTA: Bone-Seeking Agents for Imaging and TherapyJournal of Medicinal Chemistry, 2008
- Production logistics of 177Lu for radionuclide therapyApplied Radiation and Isotopes, 2003
- Radiochemical separation of no-carrier-added as produced via the processApplied Radiation and Isotopes, 2000